January 11, 2016
Office of Public Affairs
655 West Baltimore Street
Bressler Research Building 14-002
Baltimore, Maryland 21201-1559
Contact Media Relations
Tuesday, August 09, 2022
A new study, published in The Lancet Global Health, finds typhoid conjugate vaccine, Typbar TCV®, provides immunity for up to 3 years in children as young as 9 months old in Malawi. The research – conducted by the Blantyre Malaria Project, Malawi-Liverpool-Wellcome Trust, and researchers at the Center for Vaccine Development and Global Health (CVD) at the University of Maryland School of Medicine (UMSOM) – found that the TCV vaccine is safe and well tolerated. Importantly, the vaccine can be given to 9-month-old infants at the same time as routine measles-rubella vaccinations without reducing the immune response to either vaccine.
Monday, August 08, 2022
New Study Finds Rapid Decline in Vaccine-Boosted Neutralizing Antibodies Against Omicron Subvariant BA.5
A study led in part by investigators at the University of Maryland School of Medicine’s (UMSOM) Center for Vaccine Development and Global Health found that although COVID-19 booster vaccinations in adults elicit high levels of neutralizing antibodies against the Omicron variant of SARS-CoV-2, those antibody levels decrease substantially within three months. Kirsten E. Lyke, MD, Professor of Medicine at UMSOM and scientist at CVD, is Co-Chair and site Principal Investigator for the study, and Meagan Deming, MD, PhD, Assistant Professor of Medicine at the UMSOM, also a scientist at CVD, is Vice-Chair of the study, which is a collaboration between investigators at the UMSOM’s CVD and the Institute of Human Virology (IHV).
Thursday, March 24, 2022
UM School of Medicine Leads Research to Assess Meningococcal Vaccine for Infants and Young Children in Africa
Researchers at the University of Maryland School of Medicine (UMSOM)’s Center for Vaccine Development & Global Health (CVD) are leading a study to evaluate the use of a pentavalent – or five in one – meningococcal conjugate vaccine (NmCV-5) among infants and young children in the meningitis belt of sub-Saharan Africa. This is the final and pivotal study for World Health Organization (WHO) prequalification of this vaccine, which is the last stage to make the vaccine available for low- and middle-income countries.
Thursday, September 16, 2021
First Efficacy Results from Africa find Typhoid Vaccine to offer 84 Percent Protection against Typhoid Fever
A new study, published in the New England Journal of Medicine, finds a single dose of typhoid conjugate vaccine (TCV) – the only typhoid vaccine licensed for children as young as 6 months – is safe and 84 percent effective in protecting against typhoid in Blantyre, Malawi. These are the first efficacy results from Africa and part of a five-year, multi-country project to accelerate introduction of TCV.
Wednesday, November 20, 2019
Two UM School of Medicine Experts Receive Prestigious 2019 Bailey K. Ashford Medal for Distinguished Work in Tropical Medicine
The American Society of Tropical Medicine and Hygiene (ASTMH) awarded the Bailey K. Ashford Medal for distinguished work in tropical medicine to two experts at the University of Maryland School of Medicine’s Center for Vaccine Development and Global Health (CVD): Sharon Tennant, PhD, Associate Professor of Medicine, and Shannon Takala-Harrison, PhD, Associate Professor of Medicine.
Tuesday, March 20, 2018
Vaccine experts at the University of Maryland School of Medicine (UMSOM) have begun multiple clinical trials of vaccines designed to protect against H7N9, an avian influenza virus that was first reported in humans in 2013 in China.
Tuesday, October 31, 2017
University of Maryland School of Medicine Researchers Studying New Approach to Fighting Antibiotic-Resistant Wound Infections
Antibiotic resistance to serious wound and systemic infections is a growing concern, particularly among those injured in combat. Researchers at the University of Maryland School of Medicine (UM SOM) are studying how to fend off deadly infections by targeting the body’s immune response to harmful bacteria.
Friday, December 23, 2016
An experimental Ebola vaccine was highly protective against the deadly virus in a major trial in Guinea, according to a new study that included researchers from the University of Maryland School of Medicine (UM SOM).